Passage of the Harrison Act and prohibition of heroin manufacture

Passage of the Harrison Act and prohibition of heroin manufacture mark a turning point in the book’s history of opioids: as warnings about addiction mounted, access to narcotics moved away from ordinary medical and commercial channels, while people who remained dependent were increasingly treated as criminals rather than patients. The 1914 restrictions and the 1924 ban on heroin manufacture were distinct steps, but together they frame a lasting change in how addiction was understood and governed.

Warnings and the changing medical picture

By 1900, more than 250,000 Americans were addicted to opium-derived painkillers. Heroin, meanwhile, had initially been welcomed as a cough suppressant and promoted as a substitute for morphine. Despite early cautions about its dangers, it remained available at American drugstores and by mail order for eight years. That period of access was followed by mounting evidence of harm: in 1906 the American Medical Association issued a stronger warning about heroin dependence, while hospital admissions related to heroin were rising in New York and Philadelphia in the 1910s and 1920s. Officials increasingly recognized addiction among both people who had been injured and recreational users.

This alarm also followed earlier criticism of medical practice. In 1895, a Brooklyn doctor had warned colleagues against leaving morphine and syringes with patients to use whenever pain arose, noting that dependence could develop after only a few doses. The book sets that concern beside later public claims that addiction caused by doctors was exceedingly rare, emphasizing how often the medical understanding of opioid risk has shifted—and how readily prior experience has been forgotten.

Restrictions and the later manufacturing ban

The Harrison Narcotics Act of 1914 severely restricted the sale and possession of heroin and other narcotic drugs. The book distinguishes this measure from the subsequent prohibition on heroin manufacture: manufacture was outlawed by 1924, twenty-six years after Bayer’s heroin pill came to market. The sequence moved from open retail and mail-order availability toward legal restriction and then a ban on manufacture; it did not erase dependence among people already using opioids.

By the 1930s, people who remained addicted increasingly relied on criminal drug networks to obtain heroin and stave off withdrawal. The shift in supply was accompanied by a shift in the language and social status attached to users. The drug’s history was no longer chiefly told through its medical uses or through the experiences of people who had become dependent while receiving treatment. Instead, the public image centered on illicit markets and criminality.

From patients to criminals

The book describes heroin users of the 1930s as increasingly working-class, including children of immigrants, alongside a growing number of jazz musicians and other creative people. Users were labeled junkies, a category associated with inner-city life and with collecting and selling scrap metal to support drug use. The earlier figure of the doctor-addicted patient—once familiar in small towns—receded from public memory. As upper- and middle-class opium and morphine users died out, those still addicted were classified as criminals rather than patients.

That reclassification is central to the event’s significance. The law addressed the circulation of narcotics, but the historical account also traces how restriction and stigma helped make criminality the dominant public frame for addiction. The change in labels mattered: it obscured medical pathways into dependence and narrowed the imagined identity of the person who used opioids.

A legacy of uneven medicine and enforcement

The book places this older criminal frame beside the later expansion of medical opioid use. In 1996, Purdue Pharma introduced OxyContin amid a campaign that presented addiction risk as low and the drug as appropriate for a wide range of pain. At the same time, the medical movement to treat pain as the fifth vital sign and new mandatory pain-assessment standards encouraged routine attention to pain. The standards made pain easier to quantify, but the book notes that pain scales could give an appearance of objectivity without reliably improving outcomes, while their use contributed to increased opioid prescribing and abuse. This later expansion did not simply reverse the earlier prohibition; it shows how medical institutions could alternately restrict and normalize opioid use.

The account also connects the criminalization of drug use to unequal treatment across racial groups. In Roanoke, heroin had once been widely regarded as an inner-city drug associated with Black users, while the later prescription-opioid crisis disproportionately affected white communities. The book reports that physicians prescribed painkillers to people of color at much lower rates, and that drug enforcement and imprisonment fell disproportionately on Black and Hispanic people. These contrasts do not make the 1914 law the sole cause of later disparities. They show instead how the boundary between patient and criminal has been drawn unevenly, with medical access and criminal punishment operating differently across populations.